On February 5, 2015, Saitoh, Morihisa; Yogo, Takatoshi; Kamei, Taku; Tokunaga, Norihito; Ohba, Yusuke; Yukawa, Takafumi published a patent.Application In Synthesis of 6,7-Dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride The title of the patent was Preparation of pyridinylpyrrolidinone heterocyclic compounds as tyrosine kinase 2 inhibitors, and preventive and therapeutic methods for autoimmune disease. And the patent contained the following:
The heterocyclic compounds are represented by formula I [ring A = addnl. (un)substituted pyrrolidine; R1, R2, R4 = H, substituent; R3 = H, halo, halo-(un)containing C1-6 alkyl, amino, halo-(un)containing C1-6 alkyl(mono or di-)amino; R5 = H, (un)substituted C1-6 alkyl, (un)substituted C6-14 aryl, (un)substituted aromatic heterocycle, acyl]. Thus, reacting Et cyano(cyclopropyl)acetate (preparation given) with 2-benzyl(2-bromoethyl)carbamate, reacting with sodium hydride to obtain 3-cyclopropyl-2-oxopyrrolidine-3-carbonitrile, separating 3-cyclopropyl-2-oxopyrrolidine-3-carbonitrile by chiral HPLC to prepare (3S)-cyclopropyl-2-oxopyrrolidine-3-carbonitrile, reacting (3S)-cyclopropyl-2-oxopyrrolidine-3-carbonitrile with 2-bromo-4-fluoropyridine, and coupling with 5-(morpholin-4-yl)pyridin-2-amine, gave (3S)-3-cyclopropyl-1-[2-[[5-(morpholin-4-yl)pyridin-2-yl]amino]pyridin-4-yl]-2-oxopyrrolidine-3-carbonitrile with tyrosine kinase 2 (Tyk2) inhibitory activity (1 μM) 99%. Formulations containing I are given. The experimental process involved the reaction of 6,7-Dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride(cas: 1187830-46-1).Application In Synthesis of 6,7-Dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride
The Article related to pyridinylpyrrolidinone tyk2 inhibitor preparation autoimmune therapeutic psoriasis rheumatoid, arthritis inflammatory sjoegren behcet multiple sclerosis systemic lupus erythematosus and other aspects.Application In Synthesis of 6,7-Dihydro-5H-pyrrolo[3,4-d]pyrimidine hydrochloride
Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia